Eprosartan
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Eprosartan
Eprosartan: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Eprosartan, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 2 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| None | None |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| None | None |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| hypertension |
| hypertensive disorder |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13861M | Teveten | Tablet 600 mg (as mesilate) | Valid |
Safety Considerations
- Contraindications (from knowledge-graph drug-disease edges, not label text): pancreatitis, systemic lupus erythematosus (including paediatric), potassium deficiency, diabetes mellitus, diabetic ketoacidosis, hyperuricaemia, hypotensive disorder, hyperparathyroidism, osteitis fibrosa, hepatic coma and encephalopathy, neonatal jaundice, anuria, gout, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disorders, and renal artery obstruction. These come from a model knowledge graph and should be verified against the Product Information. Renal artery obstruction is particularly relevant to the predicted renovascular indication.
- Drug Interactions: 84 interactions were identified in total. Major interactions include potassium citrate and potassium bicarbonate (hyperkalaemia risk). Moderate interactions include corticosteroids (hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide), acetylsalicylic acid, SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin), insulins (aspart, degludec, detemir), bupropion, morphine, dronabinol, and bowel-preparation agents (picosulfuric acid, sodium sulfate, polyethylene glycol with electrolytes).
Label warnings and contraindications were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.